Literature DB >> 174379

GM2-gangliosidosis, AB variant: clinico-pathological study of a case.

C M de Baecque, K Suzuki, I Rapin, A B Johnson, D L Whethers.   

Abstract

Clinical and neuropathological studies of a case of AB variant GM2-gangliosidosis have been presented. The patient was a 14 months old black female infant who had "black cherry spot" in the retinas. The total activities of beta-galactosidase and N-acetyl-beta-hexosaminidase, as well as the proportion of hexosaminidase A and B components in her serum and leukocytes were normal when the assays were carried out with artificial fluorogenic substrate. Diagnosis of GM2-gangliosidosis AB variant was established by an abnormal increase of GM2-ganglioside in the biopsied brain tissue, similar to classical Tay-Sachs disease. Her clinical manifestation appeared to be similar but somewhat milder than those of classical Tay-Sachs disease. Light microscopic features of the cerebral biopsy were also closely similar to Tay-Sachs disease and Sandhoff disease but gliosis and neuronal loss were less pronounced. Electron microscopic study revealed numerous membranous cytoplasmic bodies (MCB) and zebra bodies in neurons. In addition, varieties of large intracytoplasmic inclusions in astrocytes, a feature distinctly different from classical Tay-Sachs disease, were observed. Numerous cytoplasmic inclusions were also present in oligodendroglia, pericytes and microglial cells.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 174379     DOI: 10.1007/bf00688395

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  42 in total

1.  Adult (chronic) GM2 gangliosidosis. Atypical spinocerebellar degeneration in a Jewish sibship.

Authors:  I Rapin; K Suzuki; K Suzuki; M P Valsamis
Journal:  Arch Neurol       Date:  1976-02

2.  Neuronal Enzyme Alterations in Tay-Sachs Disease.

Authors:  S S Lazarus; B J Wallace; B W Volk
Journal:  Am J Pathol       Date:  1962-11       Impact factor: 4.307

3.  [Sandhoff's disease (GM2 gangliosidosis, type 2). Clinical, biochemical and anatomo-clinical study].

Authors:  M Vidailhet; N Neimann; G Grignon; P Hartemann; M Philippart; P Paysant; P Nabet; J Floquet
Journal:  Arch Fr Pediatr       Date:  1973-01

4.  A case of juvenile lipidosis: electron microscopic, histochemical and biochemical studies.

Authors:  K Suzuki; A B Johnson; E Marquet; K Suzuki
Journal:  Acta Neuropathol       Date:  1968-09-02       Impact factor: 17.088

5.  Deficient hexozaminidase activity in an exceptional case of Tay-Sachs disease with additional storage of kidney globoside in visceral organs.

Authors:  K Sandhoff; U Andreae; H Jatzkewitz
Journal:  Life Sci       Date:  1968-03-15       Impact factor: 5.037

6.  GM1-gangliosidosis (gneralized gangliosidosis). Morphology and chemical pathology.

Authors:  K Suzuki; G C Chen
Journal:  Pathol Eur       Date:  1968

7.  Krabbe's globoid cell leukodystrophy: deficiency of glactocerebrosidase in serum, leukocytes, and fibroblasts.

Authors:  Y Suzuki; K Suzuki
Journal:  Science       Date:  1971-01-08       Impact factor: 47.728

8.  Cerebral lipids in a case of systemic Gm2-gangliosidosis of a late infantile type.

Authors:  C Klibansky; A Saifer; N I Feldman; L Schneck; B W Volk
Journal:  J Neurochem       Date:  1970-03       Impact factor: 5.372

9.  Detection of Tay-Sachs disease heterozygotes by assay of hexosaminidase A in serum and leukocytes.

Authors:  Y Suzuki; P H Berman; K Suzuki
Journal:  J Pediatr       Date:  1971-04       Impact factor: 4.406

10.  [Tay-Sachs disease with hexosaminidase deficiency. Clinical, morphological and biochemical findings in a case with visceral storage of renal globosides].

Authors:  H Pilz; D Müller; K Sandhoff; V ter Meulen
Journal:  Dtsch Med Wochenschr       Date:  1968-09-27       Impact factor: 0.628

View more
  8 in total

Review 1.  Biochemistry and genetics of gangliosidoses.

Authors:  K Sandhoff; H Christomanou
Journal:  Hum Genet       Date:  1979       Impact factor: 4.132

Review 2.  Basic findings and current developments in sphingolipidoses.

Authors:  H Pilz; R Heipertz; D Seidel
Journal:  Hum Genet       Date:  1979-03-12       Impact factor: 4.132

Review 3.  Progress in investigations of sphingolipidoses.

Authors:  M Adachi; L Schneck; B W Volk
Journal:  Acta Neuropathol       Date:  1978-08-07       Impact factor: 17.088

4.  The AB-variant of GM2-gangliosidosis. Clinical, biochemical, and pathological studies of two patients.

Authors:  J E Goldman; T Yamanaka; I Rapin; M Adachi; K Suzuki; K Suzuki
Journal:  Acta Neuropathol       Date:  1980       Impact factor: 17.088

5.  Mutation in GM2A Leads to a Progressive Chorea-dementia Syndrome.

Authors:  Mustafa A Salih; Mohammed Z Seidahmed; Heba Y El Khashab; Muddathir H A Hamad; Thomas M Bosley; Sabrina Burn; Angela Myers; Megan L Landsverk; Patricia L Crotwell; Kaya Bilguvar; Shrikant Mane; Michael C Kruer
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2015-07-09

6.  Atypical juvenile presentation of GM2 gangliosidosis AB in a patient compound-heterozygote for c.259G > T and c.164C > T mutations in the GM2A gene.

Authors:  Carla Martins; Catherine Brunel-Guitton; Anne Lortie; France Gauvin; Carlos R Morales; Grant A Mitchell; Alexey V Pshezhetsky
Journal:  Mol Genet Metab Rep       Date:  2017-04-07

Review 7.  Genetics and Therapies for GM2 Gangliosidosis.

Authors:  Maria Begona Cachon-Gonzalez; Eva Zaccariotto; Timothy Martin Cox
Journal:  Curr Gene Ther       Date:  2018       Impact factor: 4.391

8.  The GM2 gangliosidoses: Unlocking the mysteries of pathogenesis and treatment.

Authors:  Camilo Toro; Mosufa Zainab; Cynthia J Tifft
Journal:  Neurosci Lett       Date:  2021-08-25       Impact factor: 3.046

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.